United States - English - NLM (National Library of Medicine)

avera mckennan hospital - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50 mg

United States - English - NLM (National Library of Medicine)

cardinal health - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50 mg

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. renal homotransplantation: azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti-b-cell alloantigen antibody, and other variables. the effect of azathioprine on these variables has not been tested in controlled trials. rheumatoid arthritis : azathioprine tablets are indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine. the combined use of azathioprine with disease modifying anti-rheumatic drugs (dmards) has not been

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals, inc - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - indications and usage: azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. renal homotransplantation: azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti b-cell alloantigen antibody, and other variables. the effect of azathioprine on these variables has not been tested in controlled trials. rheumatoid arthritis: azathioprine is indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine. the combined use of azathioprine with disease modifying anti-rheumatic drugs (dmards) has not been

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. renal homotransplantation: azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti-b-cell alloantigen antibody, and other variables. the effect of azathioprine on these variables has not been tested in controlled trials. rheumatoid arthritis: azathioprine tablets are indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine. the combined use of azathioprine with disease modifying anti-rheumatic drugs (dmards) has not been studied for either added benefit or unexpected adverse effects. the use of azathioprine tablets with these agents cannot be recommended. azathioprine tablets should not be given to patients who have shown hypersensitivity to the drug. azathioprine tablets should not be used for treating rheumatoid arthritis in pregnant women. patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine tablets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400; macrogol 8000; sunset yellow fcf aluminium lake; carmine; indigo carmine aluminium lake - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thromocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thrombocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400; macrogol 8000; sunset yellow fcf aluminium lake; carmine; indigo carmine aluminium lake - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumetoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thromocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thrombocytopenic purpura.